Skip to content
Screener

United Therapeutics UTHR Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$790.2MMiss by $22.9M
EPS$7.70Beat by $0.57
Revenue estimate$813.1M
EPS estimate$7.13

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$789.5M
EPS estimate$6.44

Financials

Q4 2025

Income statement

See full
Revenue$790.2M+7.4%
Gross profit$686.8M+4.1%
Operating income$356.7M-0.3%
Net income$364.3M+20.9%
EPS (diluted)$7.69+23.8%

Balance sheet

See full
Cash & equivalents$1.6B-8.3%
Total equity$7.1B+10.1%
Total assets$7.9B+7.0%

Cash flow

See full
Operating cash flow$346.2M+1.5%
CapEx$172.9M+99.4%
Free cash flow$173.3M-31.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$20.98B+33.2%
P/E15.7×+2.5×
P/S6.6×+1.1×

Profitability

See full
Gross margin87.9%-1.3pp
Operating margin46.9%-1.0pp
Net margin41.9%+0.4pp
FCF margin32.7%-4.9pp

Returns & leverage

See full
Return on equity19.7%+0.5pp
Current ratio6.6×+1.4×

Segments

By product

See full
Tyvaso DPI$338.6M+23.9%
Remodulin$128.0M-4.8%
Nebulized Tyvaso$125.7M-11.9%
Orenitram$121.2M+12.4%
Unituxin$62.3M-7.7%

FAQ

When did United Therapeutics report Q4 2025 earnings?
United Therapeutics (UTHR) reported Q4 2025 earnings on February 25, 2026 before market open.
What were United Therapeutics's Q4 2025 revenue and EPS?
United Therapeutics reported revenue of $790.2M and eps of $7.70 for Q4 2025.
Did United Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $813.1M by $22.9M. EPS beat the consensus estimate of $7.13 by $0.57.
How did United Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.4% from $735.9M a year earlier and eps grew 24.4% from $6.19.
Where can I find United Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001082554-26-000007) and the 10-K periodic report (0001082554-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.